TLR9 and neoplasm: In vivo evidence that F4/80+CD169+ MSMs and F4/80+CD169− MCMs are capable of cross-presentation comes from the finding that only these cells can induce antitumor effects through stimulation of tumor-specific CD8+ T lymphocytes when targeted by a nanogel packed with tumor-specific synthetic long peptide antigen (LPA) and a TLR9 agonist (32).